Physician profile
Rajesh Behl
NPI 1104844174
$583,925.31
in general payments reported to CMS, 2019-2025
64 companies · $165K in 2025
The $165K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $20K · 2021: $80K · 2022: $154K · 2023: $60K · 2024: $56K · 2025: $165K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $96K · Consulting Fee: $88K · Honoraria: $59K · Travel and Lodging: $26K · Food and Beverage: $12K · Education: $47.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,970.00 |
| Consulting Fee | $88,290.50 |
| Honoraria | $58,900.00 |
| Travel and Lodging | $25,923.21 |
| Food and Beverage | $12,028.10 |
| Education | $47.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $165,225.44 | 2020-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $103,779.44 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Abbvie INC. | $69,497.53 | 2019-2025 | Venclexta, Epkinly |
| Janssen Biotech, INC. | $42,345.51 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Glaxosmithkline, LLC. | $28,765.29 | 2021-2025 | Jemperli, Zejula |
| Adc Therapeutics America, INC. | $24,640.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $23,970.79 | 2019-2025 | |
| Incyte Corporation | $19,863.10 | 2021-2025 | Monjuvi, Monjuvi, Jakafi |
| Genmab U.S., INC. | $17,328.52 | 2023-2025 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $13,866.01 | 2019-2025 | Opdivo, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $11,182.58 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Kite Pharma, INC. | $11,071.97 | 2020-2025 | Yescarta |
| Celgene Corporation | $8,255.28 | 2019-2025 | Reblozyl |
| Jazz Pharmaceuticals INC. | $7,184.66 | 2019-2025 | |
| Beigene USA, INC. | $7,116.34 | 2020-2025 | Brukinsa |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,841.70 | 2019-2025 | |
| Syndax Pharmaceuticals, INC. | $4,386.73 | 2025 | Revuforj |
| Amgen INC. | $4,252.45 | 2019-2024 | Blincyto |
| Gilead Sciences, INC. | $4,059.00 | 2023-2025 | Trodelvy |
| Invivyd INC | $2,838.43 | 2025 | Pemgarda |
| Daiichi Sankyo INC. | $2,032.88 | 2020-2025 | Enhertu, Enhertu, Datroway |
| Janssen Scientific Affairs, LLC | $1,362.50 | 2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $1,022.95 | 2020-2025 | Gavreto, Rezlidhia, Tavalisse |
| Adaptive Biotechnologies Corporation | $1,000.00 | 2021 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Merck Sharp & Dohme LLC | $434.50 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Array Biopharma INC | $265.66 | 2025 | Braftovi, Mektovi, Tukysa |
| Exelixis INC. | $136.78 | 2019-2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $134.92 | 2019-2025 | Pyrukynd |
| Seagen INC. | $113.61 | 2019-2023 | Adcetris |
| Integra Lifesciences Corporation | $112.81 | 2025 | Integra, Omnigraft, Surgimend |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.21 | 2019-2025 | |
| Eisai INC. | $94.25 | 2019-2025 | |
| Genzyme Corporation | $86.04 | 2025 | |
| Progenics Pharmaceuticals, INC. | $85.81 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $81.89 | 2019-2023 | Imbruvica |
| Iovance Biotherapeutics, INC. | $77.96 | 2025 | Amtagvi |
| Beone Medicines USA, INC. | $68.92 | 2025 | Brukinsa |
| Astellas Pharma US INC | $63.01 | 2019-2025 | Vyloy |
| Springworks Therapeutics, INC. | $48.42 | 2025 | Gomekli, Ogsiveo |
| Alexion Pharmaceuticals, INC. | $48.27 | 2020-2025 | Ultomiris |
| Taiho Oncology, INC. | $42.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.61 | 2019-2025 | |
| Sobi, INC | $36.37 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $34.57 | 2025 | Onivyde |
| Tempus Ai, INC | $33.67 | 2025 | Xt Cdx |
| Coherus Oncology, INC. | $32.84 | 2025 | Loqtorzi |
| Spectrum Pharmaceuticals INC. | $30.58 | 2025 | Rolvedon |
| Pharmaessentia USA Corporation | $29.04 | 2025 | Besremi |
| Genentech USA, INC. | $28.87 | 2025 | Columvi, Lunsumio, Polivy |
| Aveo Pharmaceuticals, INC. | $28.51 | 2025 | |
| Puma Biotechnology, INC. | $26.86 | 2025 | |
| Kyowa Kirin, INC. | $26.77 | 2025 | |
| Tesaro, INC. | $25.61 | 2019 | |
| Fennec Pharmaceuticals, INC. | $25.09 | 2025 | Fyarro |
| Legend Biotech USA INC. | $24.20 | 2025 | Carvykti |
| Lilly USA, LLC | $23.73 | 2025 | Verzenio, Jaypirca |
| Recordati_rare_diseases_inc. | $22.82 | 2025 | Enjaymo |
| Deciphera Pharmaceuticals INC. | $21.95 | 2025 | Romvimza, Qinlock |
| Emd Serono, INC. | $21.85 | 2025 | |
| Clovis Oncology, INC. | $21.16 | 2019 | |
| Sanofi US Services INC. | $20.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.88 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Behl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.